Source: http://www.asmscience.org/content/book/10.1128/9781555815974.ch24
Timestamp: 2019-04-25 06:14:27+00:00

Document:
1. Berkhout, R. J.,, J. N. Bouwes Bavinck, and, J. ter Schegget. 2000. Persistence of human papillomavirus DNA in benign and (pre)malignant skin lesions from renal transplant recipients. J. Clin. Microbiol. 38 :2087– 2096.
2. Bosch, F. X.,, A. Lorincz,, N. Munoz,, C. J. Meijer, and, K. V. Shah. 2002. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55: 244– 265.
3. Bosch, F. X.,, M. M. Manos,, N. Munoz,, M. Sherman,, A. M. Jansen,, J. Peto,, M. H. Schiffman,, V. Moreno,, R. Kurman,, K. V. Shah, et al. 1995. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst. 87: 796– 802.
4. Bosch, F. X.,, N. Munoz,, S. de Sanjose,, E. Guerrerro,, A. M. Ghaffari,, J. Kaldor,, X. Castellsague,, K. V. Shah, and, A. M. Gaffari. 1994. Importance of human papillomavirus endemicity in the incidence of cervical cancer: an extension of the hypothesis on sexual behavior. Cancer Epidemiol. Biomarkers Prev. 3: 375– 379.
5. Boxman, I. L.,, R. J. Berkhout,, L. H. Mulder,, M. C. Wolkers,, J. N. Bouwes Bavinck,, B. J. Vermeer, and, J. ter Schegget. 1997. Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. J. Investig. Dermatol. 108: 712– 715.
6. Bunney, M. 1992. Viral Warts: Their Biology and Treatment. Oxford University Press, Oxford, United Kingdom.
7. Centers for Disease Control and Prevention. 2007. Table 42. Selected STDs and complications—initial visits to physicians’ offices, National Disease and Therapeutic Index: United States, 1966–2007. [Online.] http://www.cdc.gov/std/stats07/tables/42.htm.
8. Chuang, T. Y.,, H. O. Perry,, L. T. Kurland, and, D. M. Ilstrup. 1984. Condyloma acuminatum in Rochester, Minn., 1950–1978. I. Epidemiology and clinical features. Arch. Dermatol. 120: 469– 475.
9. Clifford, G.,, S. Franceschi,, M. Diaz,, N. Munoz, and, L. L. Villa. 2006. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24 (Suppl. 3) : S26– S34.
10. Croissant, O.,, F. Breitburd, and, G. Orth. 1985. Specificity of cytopathic effect of cutaneous human papillomaviruses. Clin. Dermatol. 3: 43– 55.
11. Cullen, A. P.,, R. Reid,, M. Campion, and, A. T. Lorincz. 1991. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J. Virol. 65: 606– 612.
12. de Koning, M. N.,, L. Struijk,, J. N. Bavinck,, B. Kleter,, J. ter Schegget,, W. G. Quint, and, M. C. Feltkamp. 2007. Betapapillomaviruses frequently persist in the skin of healthy individuals. J. Gen. Virol. 88: 1489– 1495.
13. de Roda, H.,, J. M. Walboomers,, C. J. Meijer,, E. K. Risse,, M. E. Schipper,, T. M. Helmerhorst,, O. P. Bleker,, H. Delius,, A. J. van den Brule, and, P. J. Snijders. 1994. Analysis of cytomorphologically abnormal cervical scrapes for the presence of 27 mucosotropic human papillomavirus genotypes, using polymerase chain reaction. Int. J. Cancer. 56: 802– 806.
14. de Villiers, E. M.,, C. Fauquet,, T. R. Broker,, H. U. Bernard, and, H. zur Hausen. 2004. Classification of papillomaviruses. Virology 324: 17– 27.
15. Dillner, J. 1999. The serological response to papillomaviruses. Semin. Cancer Biol. 9: 423– 430.
16. D’Souza, G.,, A. R. Kreimer,, R. Viscidi,, M. Pawlita,, C. Fakhry,, W. M. Koch,, W. H. Westra, and, M. L. Gillison. 2007. Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med. 356: 1944– 1956.
17. Durst, M.,, D. Glitz,, A. Schneider, and, H. zur Hausen. 1992. Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization. Virology 189: 132– 140.
18. Gissmann, L.,, L. Wolnik,, H. Ikenberg,, U. Koldovsky,, H. G. Schnurch, and, H. zur Hausen. 1983. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc. Natl. Acad. Sci. USA 80: 560– 563.
19. Gravitt, P. E.,, C. L. Peyton,, R. J. Apple, and, C. M. Wheeler. 1998. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J. Clin. Microbiol. 36: 3020– 3027.
20. Jablonska, S.,, and S. Majewski. 1972. Epidermodysplasia verriciformis: immunolgical and clinical aspects, p. 157–175. In H. zur Hausen (ed.), Human Pathogenic Papillomaviruses. Springer Verlag, Heidelberg, Germany.
21. Jenson, A. B.,, J. D. Rosenthal,, C. Olson,, F. Pass,, W. D. Lancaster, and, K. Shah. 1980. Immunologic relatedness of papillomaviruses from different species. J. Natl. Cancer Inst. 64: 495– 500.
22. Kirnbauer, R.,, N. L. Hubbert,, C. M. Wheeler,, T. M. Becker,, D. R. Lowy, and, J. T. Schiller. 1994. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J. Natl. Cancer Inst. 86: 494– 499.
23. Koutsky, L. A.,, K. A. Ault,, C. M. Wheeler,, D. R. Brown,, E. Barr,, F. B. Alvarez,, L. M. Chiacchierini, and, K. U. Jansen. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347: 1645– 1651.
24. Koutsky, L. A.,, and D. M. Harper. 2006. Chapter 13: current findings from prophylactic HPV vaccine trials. Vaccine 24 (Suppl. 3) : S114– S121.
25. Lehtinen, M.,, M. Pawlita,, K. Zumbach,, K. Lie,, M. Hakama,, E. Jellum,, P. Koskela,, T. Luostarinen,, J. Paavonen,, E. Pukkala,, E. Sigstad,, S. Thoresen, and, J. Dillner. 2003. Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later. Am. J. Obstet. Gynecol. 188: 49– 55.
26. Lorincz, A. T. 1996. Hybrid capture method for detection of human papillomavirus DNA in clinical specimens: a tool for clinical management of equivocal Pap smears and for population screening. J. Obstet. Gynaecol. Res. 22: 629– 636.
27. Manos, M. M.,, Y. Ting,, D. K. Wright,, A. J. Lewis,, T. R. Broker, and, S. M. Wolinsky. 1989. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses, p. 209–214. In M. Furth and, M. Greaves (ed.), Cancer Cells 7, Molecular Diagnostics of Human Cancer. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
28. Meisels, A.,, C. Morin, and, M. Casas-Cordero. 1982. Human papillomavirus infection of the uterine cervix. Int. J. Gynecol. Pathol. 1: 75– 94.
29. Mounts, P.,, and K. V. Shah. 1984. Respiratory papillomatosis: etiological relation to genital tract papillomaviruses. Prog. Med. Virol. 29: 90– 114.
30. Oriel, J. D. 1971. Natural history of genital warts. Br. J. Vener. Dis. 47: 1– 13.
31. Parkin, D. M.,, and F. Bray. 2006. Chapter 2: the burden of HPV-related cancers. Vaccine 24 (Suppl. 3) : S11– S25.
32. Pfister, H.,, I. Hettich,, U. Runne,, L. Gissmann, and, G. N. Chilf. 1983. Characterization of human papillomavirus type 13 from focal epithelial hyperplasia Heck lesions. J. Virol. 47: 363– 366.
33. Pfister, H.,, and J. ter Schegget. 1997. Role of HPV in cutaneous premalignant and malignant tumors. Clin. Dermatol. 15: 335– 347.
34. Ramoz, N.,, L. A. Rueda,, B. Bouadjar,, L. S. Montoya,, G. Orth, and, M. Favre. 2002. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat. Genet. 32: 579– 581.
35. Scheffner, M.,, K. Munger,, J. C. Byrne, and, P. M. Howley. 1991. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA 88: 5523– 5527.
36. Schiller, J. T.,, and D. R. Lowy. 1996. Papillomavirus-like particles and HPV vaccine development. Semin. Cancer Biol. 7: 373– 382.
37. Schiller, J. T.,, and D. Nardelli-Haefliger. 2006. Chapter 17: second generation HPV vaccines to prevent cervical cancer. Vaccine. 24 (Suppl. 3) : S147– S153.
38. Schneider, A.,, and L. A. Koutsky. 1992. Natural history and epidemiologic features of genital HPV infection, p. 25–52. In N. Munoz,, F. X. Bosch,, K. V. Shah, and, A. Meheus (ed.), The Epidemiology of Human Papillomavirus and Cervical Cancer. International Agency for Research on Cancer, Lyon, France.
39. Silins, I.,, E. Avall-Lundqvist,, A. Tadesse,, K. U. Jansen,, U. Stendahl,, P. Lenner,, K. Zumbach,, M. Pawlita,, J. Dillner, and, B. Frankendal. 2002. Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients. Gynecol. Oncol. 85: 333– 338.
40. Silverberg, M. J.,, P. Thorsen,, H. Lindeberg,, L. A. Grant, and, K. V. Shah. 2003. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet. Gynecol. 101: 645– 652.
41. Skegg, D. C.,, P. A. Corwin,, C. Paul, and, R. Doll. 1982. Importance of the male factor in cancer of the cervix. Lancet ii: 581– 583.
42. Viscidi, R. P.,, Y. Sun,, B. Tsuzaki,, F. X. Bosch,, N. Munoz, and, K. V. Shah. 1993. Serologic response in human papilloma-virus-associated invasive cervical cancer. Int. J. Cancer. 55: 780– 784.
43. Walboomers, J. M.,, M. V. Jacobs,, M. M. Manos,, F. X. Bosch,, J. A. Kummer,, K. V. Shah,, P. J. Snijders,, J. Peto,, C. J. Meijer, and, N. Munoz. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189: 12– 19.
44. Wu, T. C. 1994. Immunology of the human papilloma virus in relation to cancer. Curr. Opin. Immunol. 6: 746– 754.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.